By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
| Currency | US Dollars |
| Share Price | $ 164.58 |
| Change Today | $ 0.16 |
| % Change | 0.10 % |
| 52 Week High | $187.62 |
| 52 Week Low | $118.84 |
| Volume | 251,928 |
| Shares Issued | 145.80m |
| Market Cap | $23,996m |
| Beta | 0.01 |
| RiskGrade | 259 |
| Strong Buy | 8 |
| Buy | 6 |
| Neutral | 19 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 34 |

| Time | Volume / Share Price |
| 11:16 | 100 @ $164.58 |
| 11:16 | 129 @ $164.54 |
| 11:16 | 100 @ $164.51 |
| 11:15 | 100 @ $164.51 |
| 11:15 | 100 @ $164.43 |
You are here: research